Cutting edge: Cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain

Journal of Immunology

Volumn 171, Issue 5, 2003, Pages 2187-2191

  Calzascia, Thomas ^a   Di Berardino Besson, Wilma ^a   Wilmotte, Rick ^a   Masson, Frédérick ^a   De Tribolet, Nicolas ^a   Dietrich, Pierre Yves ^a   Walker, Paul R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

H2 ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BRAIN TISSUE; CANCER GRAFT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; GLIOMA CELL; IMMUNOMODULATION; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; TUMOR IMMUNOLOGY;

EID: 0041428161     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.5.2187     Document Type: Article

References (26)

1. Fabry, Z., C. S. Raine, and M. N. Hart. 1994. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol. Today 15:218.
2. Stupp, R., P. Y. Dietrich, K. S. Ostermann, A. Pica, I. Maillard, P. Maeder, R. Meuli, R. Janzer, G. Pizzolato, R. Miralbell, et al. 2002. Promising survival for patients with newly diagnosed gliablastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20:1375.
3. Gordon, L. B., S. C. Nolan, B. R. Ksander, P. M. Knopf, and C. J. Harling-Berg. 1998. Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation. J. Neuroimmunol. 88:77.
4. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA 93:10399.
5. Okada, H., H. Tahara, M. R. Shurin, J. Attanucci, K. M. Giezeman-Smits, W. K. Fellows, M. T. Lotze, W. H. Chambers, and M. E. Bozik. 1998. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int. J. Cancer. 78:196.
6. + T cell adoptive immunotherapy. Immunity 13:265.
7. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
8. Hickey, W. F. 1999. Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol. 11:125.
9. Campbell, I. L. 2001. Cytokine-mediated inflammation and signaling in the intact central nervous system. Prog. Brain Res. 132:481.
10. Zeltzer, P. M., B. Moilanen, J. S. Yu, and K. L. Black. 1999. Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application. Childs Nerv. Syst. 15:514.
11. Neumann, H., I. M. Medana, J. Bauer, and H. Lassmann. 2002. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25:313.
12. Katz-Levy, Y., K. L. Neville, A. M. Girvin, C. L. Vanderlugt, J. G. Pope, L. J. Tan, and S. D. Miller. 1999. Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J. Clin. Invest. 104:599.
13. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet, and P. Y. Dierrich. 2000. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J. Immunol. 165:3128.
14. Mukai, S., J. Kjaergaard, S. Shu, and G. E. Plautz. 1999. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 59:5245.
15. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058.
16. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
17. Norbury, C. C., and L. J. Sigal. 2003. Cross priming or direct priming: is that really the question? Curr. Opin. Immunol. 15:82.
18. Nguyen, L. T., A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi. 2002. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med 195:423.
19. Spiotto, M. T., P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y. X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17:737.
20. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation in viral immunity and self-tolerance. Nat. Rev. Immunol. 1:126.
21. + T cells results in antigen-specific T-cell tolerance. Nat. Med. 6:1348.
22. Redwine, J. M., and C. F. Evans. 2002. Markers of central nervous system glia and neurons in vivo during normal and pathological conditions. Curr. Top. Microbiol. Immunol. 265:119.
23. Facoerri, A., E. Capelli, and R. Nano. 2001. HLA class I molecules expression: evaluation of different immunocytochemical methods in malignant lesions. Anticancer Res. 21:2435.
24. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549.
25. Benedetti, S., B. Pirola, B. Pollo, L. Magrassi, M. G. Bruzzone, D. Rigamonti, R. Galli, S. Selleri, F. Di Meco, C. De Fraja, et al. 2000. Gene therapy of experimental brain rumors using neural progenitor cells. Nat. Med. 6:447.
26. + T cells in a model for multiple sclerosis. J. Exp. Med. 194:669.